MedInCell Stock Drops 3.22% Despite a 66% Surge Over the Year
The stock of the Montpellier-based biotech company fell by 3.22% this Monday during the session, to 23.48 euros, amid a significant downturn of the CAC 40. This decline occurs even though the stock still showed a weekly gain of over 1% and maintains an annual performance of more than 66%.
In mid-morning trading, MedInCell is trading at 23.48 euros, down 3.22% from last Friday's close of 24.26 euros. The stock is following the downtrend of the Parisian market: the CAC 40 is down 1.13% during the session, while the SBF 120 is down 1.08%. Among comparable pharmaceutical sector stocks, Sanofi is down 1.50% and UCB loses 3.33%, indicating broader selling pressure on the European healthcare sector. Over three months, MedInCell has seen a decline of nearly 14%, although the annual dynamics remain very positive with a gain of 66.41%. The next major event for the company is scheduled for June 16, the date of the annual results publication for the fiscal year 2025-2026, which could be a crucial catalyst for the stock's direction.
Technical Analysis
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
From a technical standpoint, MedInCell's stock price is above its 20-day (22.59 euros) and 50-day (22.89 euros) moving averages, indicating a short-term upward trend. The crossing of these thresholds in recent weeks had accompanied the stock's rebound, even though the price is now just below its 200-day moving average (23.83 euros), which acts as an intermediate resistance level. The RSI, at 59, remains in the neutral zone, far from overbought or oversold thresholds, suggesting that today's pullback does not yet reflect a pronounced technical imbalance. Within the Bollinger Bands, the stock is positioned in the upper part of the channel, at 67% of the amplitude between the lower bound (19.92 euros) and the upper bound (25.26 euros). The nearest support threshold is at 20.24 euros, while the identified resistance is at 25.12 euros, reflecting a still relatively wide corridor that mirrors the high monthly volatility of the stock, measured at 14.68%.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
